Boehringer Inks $265 Million Alzheimer’s R&D Deal For Ablynx’s Nanobodies Technology
This article was originally published in The Pink Sheet Daily
Executive Summary
The contract includes options for drug development in other neurocognitive diseases, the company tells “The Pink Sheet” DAILY.